Approval of the larger vial size may offer more dosing flexibility for pediatric and adult patients with T-cell ALL or LBL.
Originally, the FDA approved nelarabine injection for patients with T-ALL in T-LBL at a vial size of 250 mg/50mL.
The FDA has approved nelarabine injection (SH-111) at a larger vial size of 375 mg/75mL for adult and pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL), according to a press release from the developer, Shorla Oncology.1
